Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Heart transplant patients get new hope against lingering amyloid damage

NCT ID NCT05489523

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 21 times

Summary

This study tests whether the drug tafamidis can safely stop or slow the progression of ATTR amyloidosis in people who have already had a heart transplant. About 25 adults who received a heart transplant at least a year ago will take tafamidis for 12 months. Researchers will measure changes in blood protein levels, nerve function, and quality of life to see if the drug helps control the disease without causing serious side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRANSTHYRETIN CARDIAC AMYLOIDOSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Cedars-Sinai

    RECRUITING

    Beverly Hills, California, 90211, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Columbia University Medical Center

    RECRUITING

    New York, New York, 10032, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • UT Southwestern Medical Center

    RECRUITING

    Dallas, Texas, 75390, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.